Clinical Trials Startup Curebase Secures $40M in Series B Funding to Democratize Access to Clinical Trials | tech news

| |


One of the lessons of the Covid pandemic is how research institutions, governments and pharmaceutical companies have worked together to develop effective vaccines to cure the deadly coronavirus. The pandemic is also a reminder of the need to accelerate clinical drug development. That’s why San Francisco-based clinical trials start-up Curebase aims to bring high-quality medical innovations to patients faster and improve human well-being through more efficient clinical trials.

Today, Curebase announced it has secured $40 in Series B funding for its decentralized clinical trials and patient-centric software, which aims to democratize access to clinical trials. The round, which brings Curebasse total funding of $59 million, was led by Industry Ventures with participation from new institutional investors including Acrew Capital, World Innovation Lab and Positive Sum.

The funding also included existing investors GGV Capital, who led Series A, Bold Capital and Xfund. The round also included a strategic investment by global biopharmaceutical company Gilead Sciences to deepen its partnership with Curebase to implement DCT and hybrid capabilities in interventional studies.

Curebase will use the new capital injection to deepen its breadth of capabilities beyond the virtual experience through the more complex site and community healthcare interfaces, as well as more robust capabilities for interventional drug sponsors and global trials.

Founded in 2018 by Tom Lemberg, Curebase is a provider of decentralized clinical research software solutions and services for patients and healthcare providers. Curebase has developed a digital clinical trial assistant that would transform the way medical providers discover, activate and manage clinical trials for their patients. Curebase said it aims to make clinical trials faster and cheaper than anyone else through software that cuts recruitment times, automates manual steps and allows pharmaceutical companies to distribute their trials to clinics.

“We are pleased that investors recognize that Curebase is more than a software platform,” said company founder and CEO Tom Lemberg. “We are an end-to-end clinical trials company with global capabilities and an extensive site network of staff across virtual and hybrid sites offering everything needed to successfully run a better clinical trial.”

“It is more urgent than ever for the biopharmaceutical industry to transform the design and execution of our clinical programs in a way that radically transforms the way patients experience clinical trials. We believe that through a people-centric and technology-enhanced approach – like Curebase is doing – we can help shape a process that more effectively makes treatment options available to people in need,” said Matt Bryant, Head of Technology and Innovation at Gilead Sciences. “Curebase’s approach will help improve the quality, speed and patient diversity of clinical trials, allowing us to have a more representative population in our clinical research.”

In recent years, clinical research has traditionally suffered from recruitment, retention and diversity difficulties. Curebase’s model enables inclusion of underrepresented patient populations that would otherwise be excluded from clinical trials and broadens access to trials overall to address this challenge.

The Company’s virtual and hybrid research sites offer patients a unique opportunity to participate in clinical trials, regardless of location, through community provider facilities and home care. The Curebase platform enables sponsors and physicians from practices of all sizes to conduct clinical research more efficiently, including private practices, independent clinics and large academic research institutions. Most importantly, Curebase’s methods are primarily driven by patient-centricity to expand access to clinical trials for every patient, everywhere.



Previous

Razer Blade 15 (2022) with 240Hz OLED display, 12th gen Intel Core i9 CPU, Nvidia graphics introduced

Lenovo Yoga Slim laptop lineup updated with upgraded Intel and AMD processors

Next

Leave a Comment